Sanofi jumps in­to a piv­otal study for next-gen Pompe drug

Sanofi has added an­oth­er bad­ly-need­ed drug to its late-stage port­fo­lio. The drug, dubbed neoGAA, is be­ing ad­vanced by its big Gen­zyme unit in Boston, which has just start­ed a Phase III tri­al for a next-gen en­zyme re­place­ment ther­a­py for Pompe dis­ease.

Sanofi re­ports that the first of 96 pa­tients have been treat­ed with their ther­a­py, which they de­scribe as a sec­ond-gen­er­a­tion ap­proach to en­zyme re­place­ment, a field Gen­zyme helped pi­o­neer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.